U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096713) titled 'Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema' on July 24.
Brief Summary: This retrospective, comparative cohort study included 38 eyes from 38 patients with center-involving diabetic macular edema (DME), treated at Benha University Hospital. Patients were divided into two groups: 19 eyes received intravitreal Brolucizumab (6 mg), and 19 eyes received intravitreal Aflibercept (2 mg), with the aim of comparing their efficacy and safety over a 6-month period.
Study Start Date: Jan. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Anti-VEGF Therapy
Intervention:
DRUG: Intervention 1: Bro...